A historic shift in Canadian drug policy has occurred, as the regulators permit the availability of psilocybin fungi for therapeutic applications. Previously, these substances were severely restricted, but a mounting body of studies suggests they could offer benefits for emotional illnesses like PTSD. The new policy represents a substantial step to